Extramedullary disease in multiple myeloma: a systematic …
Mar 21, 2022 · Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow ...
Extramedullary disease in multiple myeloma - PMC - PubMed …
When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective.
Imaging finding of multiple myeloma presenting as soft-tissue …
Extramedullary involvement of multiple myeloma is an uncommon and aggressive condition characterized by proliferation of monoclonal plasma cells located outside the bone marrow. This report describes the imaging findings of a patient who presented with continuous soft-tissue disease on the ribs, suspected as extrapleural space tumors on chest CT.
Liquid biopsy of peripheral blood using mass spectrometry …
Aug 13, 2024 · Extramedullary disease in multiple myeloma (EMD) occurs when a subclone of malignant PCs migrates from the bone marrow, potentially forming tumors. EMD is categorized into primary (present at the time of MM diagnosis) and secondary (found at MM relapse).
Integration of clinical outcomes and molecular features in ...
2 days ago · Multiple myeloma (MM) is a bone marrow (BM)-based, multifocal neoplastic proliferation of plasma cells and Extramedullary disease (EMD) is defined by plasma cell neoplasms that arise in tissues ...
Expert consensus on a multidisciplinary approach for the …
Dec 18, 2024 · Multiple myeloma (MM) is the second most common hematological neoplastic disorder, with approximately 155,688 new cases diagnosed globally each year. ... A bone biopsy is invasive and painful, posing a risk of bleeding and infection, especially in patients with low platelet counts or compromised immunity. ... new extramedullary disease, or ...
Circulating Tumour Cells, Cell Free DNA and Tumour-Educated …
Aug 26, 2022 · Liquid biopsy can now be applied in clinical practice to diagnose, and monitor multiple myeloma, probably allowing a personalized treatment of the disease. Liquid biopsy is one of the fastest emerging fields in cancer evaluation.
Liquid biopsy of peripheral blood using mass spectrometry …
Aug 13, 2024 · Multiple myeloma (MM) is the second most prevalent hematological malignancy, characterized by infiltration of the bone marrow by malignant plasma cells. Extramedullary disease (EMD) represents a more aggressive condition involving the migration of a subclone of plasma cells to paraskeletal or extras …
Advances in the treatment of extramedullary disease in multiple myeloma ...
Aug 1, 2022 · Extramedullary multiple myeloma results in an adverse prognosis. Novel agents such as bortezomib, lenalidomide, pomalidomide, isatuximab and selinexor showed efficacy and were recommended to treat EMD.
Mar 19, 2020 · Extramedullary multiple myeloma (EMM) is an advanced subset of MM, defined by the presence of clonal PCs outside of the bone marrow, which is a multi-focal dis-ease of great heterogeneity and linked to poor prognosis (Bolli et al., 2014; Touzeau & Moreau, 2015). Tissue biopsy is invasive and is not always feasible.